Deliver Your News to the World

New antihypertensive PritorPlus® 80/25 and Kinzalkomb® 80/25 approved by EU Commission


Bayer Schering Pharma was granted European marketing authorization for its new antihypertensive fixed dose combination drug PritorPlus® 80/25 and Kinzalkomb® 80/25 (80 mg telmisartan/25 mg hydrochlorothiazide) by the European Commission. The new formulation will be launched in Germany later this month, to be followed soon by selected countries in the EU.

The product is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on PritorPlus® 80/12.5 and Kinzalkomb® 80/12.5 (80 mg telmisartan/12.5 mg hydrochlorothiazide), or patients who have been previously stabilized on telmisartan and hydrochlorothiazide separately at the same dosages.(1,2)

“For physicians and patients, it is often very challenging to reach the recommended blood pressure targets with the available treatments. PritorPlus® 80/25 and Kinzalkomb® 80/25 offer physicians a new therapeutical strategy to treat their hypertensive patients”, said Dr. Rahul Agrawal, Global Clinical Leader Cardiology, Bayer HealthCare.

European approval of PritorPlus® 80/25 and Kinzalkomb® 80/25 follows the submission of efficacy and safety data from 12 clinical trials performed in patients with mild to moderate hypertension. The core clinical development program consisted of two consecutive trials. The superiority of the fixed dose combination, 80 mg telmisartan/25 mg hydrochlorothiazide (T80/H25), versus 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5) was demonstrate.(1)

971 patients(1), who were inadequately controlled for their blood pressure (BP) on existing antihypertensive treatment, were enrolled in the program. Treatment with T80/H25 provided superior trough systolic and diastolic blood pressure lowering power (*) after 8 weeks treatment(1) compared to T80/H12.5. In the consecutive follow-up trial, 639 patients (633 patients evaluated for efficacy) were treated with the T80/H25 for a further 6 months. At the end of this treatment interval, the proportion of patients achieving DBP control had increased from 52.4% to 71.4%.(2) No clinically meaningful differences in the adverse event profiles of T80/H25 and T80/H12.5 were detected. No specific increased incidence was identified for all adverse events. No additional specific safety issues have been identified. (1,2)

Other studies considered by the EMEA showed that T80/H25-based treatment led to a significant greater lowered trough systolic and diastolic blood pressure than treatment with 160 mg valsartan /25 mg hydrochlorothiazide, the market-leading ARB’s high-strength combination.(3)
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them/b to future events or developments.

(*)  -1.6 mmHg, 95% CI from -2.5 to -0.6 mmHg (p=0.0012)) and -2.7 mmHg, 95% CI from -4.2 to -1.2 mmHg (p=0.0003) respectively

(1) Boehringer Ingelheim Trial Number 502.480
(2) Boehringer Ingelheim Trial Number 502.491
(3) White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Blood Press Monit. 2008 Feb;13(1):21-27


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.